Related Experiment Video
Updated: Feb 3, 2026

Identifying Protein-protein Interaction Sites Using Peptide Arrays
Published on: November 18, 2014
Design, cyclization, and optimization of MMP13-TIMP1 interaction-derived self-inhibitory peptides against chondrocyte
Wei Zhang1, Chi Zhang1, Congfeng Luo1
1Department of Orthopaedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
Abstract:
The matrix metallopeptidase 13 (MMP13) is a central regulator of chondrocyte senescence that contributes to the development and progression of osteoarthritis (OA). In the present study, the native inhibitory structure of MMP13 in complex with its natural cognate inhibitor, the tissue inhibitor of metalloproteinases 1 (TIMP1), was modeled at atomic level using a grafting-based structural bioinformatics method with existing crystal structures. The modeled complex structure was then examined in detail, from which a TIMP1 inhibitory site that directly inserts into the active site of MMP13 enzyme was identified. The inhibitory site contains a coiled inhibitory loop (ILP) and a stretched N-terminal tail (NTT); they are highly structured in the intact MMP13-TIMP1 complex interface, but exhibit a large flexibility and intrinsic disorder when split from the interface context. In vitro binding assays demonstrated that the isolated ILP and NTT peptides cannot effectively rebind at the MMP13 active site (Kd > ~100 μM or = n.d.), although they have all key interacting residues in the enzyme inhibition. In silico simulations revealed that splitting of the peptide segments from TIMP1 inhibitory site does not influence the direct intermolecular interaction between MMP13 and the peptides substantially; instead, the large conformational flexibility of these isolated peptides in absence of interface context is primarily responsible for the affinity impairment, which would incur a considerable entropy penalty upon the peptide binding to MMP13. An extended version of ILP peptide, namely eILP (63TPAMESVCGY72), was redesigned with a rational strategy to derive a number of its cyclized counterparts by introducing a disulfide bridge across the peptide two-termini; the redesign reduces the peptide flexibility in free state and constrains the peptide pre-folding to a native-like conformation, which would help the peptide binding with minimized entropy penalty. Binding assays substantiated that the affinity Kd values of four designed cyclic peptides (, , and ) were improved to 23, 67, 42 and 18 μM, respectively, from the 96 μM of linear eILP peptide.
Insights
This study models the MMP13-TIMP1 complex, revealing peptide flexibility hinders osteoarthritis drug binding. Redesigned cyclic peptides show improved MMP13 inhibition by reducing this flexibility.
Area of Science:
- Biochemistry
- Structural Biology
- Bioinformatics
Background:
- Matrix metallopeptidase 13 (MMP13) drives chondrocyte senescence and osteoarthritis (OA) progression.
- Tissue inhibitor of metalloproteinases 1 (TIMP1) is a natural inhibitor of MMP13.
Purpose of the Study:
- To model the MMP13-TIMP1 complex at atomic resolution.
- To identify the structural basis of TIMP1 inhibition and peptide binding affinity.
- To rationally design improved MMP13 inhibitors.
Main Methods:
- Grafting-based structural bioinformatics for atomic-level modeling.
- In vitro binding assays (Kd measurements).
- In silico molecular dynamics simulations.
- Rational peptide redesign and cyclization.
Main Results:
- The MMP13-TIMP1 complex model identified an inhibitory site with a coiled inhibitory loop (ILP) and N-terminal tail (NTT).
- Isolated ILP and NTT peptides showed poor MMP13 binding (Kd > 100 μM) due to conformational flexibility and entropy penalty.
- Redesigned cyclic peptides with reduced flexibility demonstrated significantly improved MMP13 binding affinities (Kd values ranging from 18 to 67 μM).
Conclusions:
- Peptide flexibility in the absence of the inhibitory interface is the primary cause of reduced binding affinity.
- Constraining peptide conformation through rational design, specifically cyclization, enhances binding to MMP13.
- This strategy offers a promising approach for developing novel osteoarthritis therapeutics targeting MMP13.
Related Concept Videos
Peptide Bonds
Replicative Cell Senescence
Factorial Design
Group Design
Intramolecular Claisen Condensation of Dicarboxylic Esters: Dieckmann Cyclization
Excitatory and Inhibitory Effects of Neurotransmitters

